Duocarmycin

Duocarmycins are a family of exceptionally potent antitumor antibiotics originally isolated from Streptomyces bacteria, with the prototypical member CC-1065 discovered in 1978. They function as sequence-selective DNA minor groove-binding agents that exert their cytotoxic effects by covalently alkylating the N3 position of adenine in AT-rich regions. This irreversible modification disrupts the DNA architecture and overstabilizes the helix, effectively blocking essential cellular processes such as replication and transcription. Because they can target both dividing and non-dividing cells, duocarmycins exhibit extreme cytotoxicity often in the picomolar range, making them highly effective against multi-drug resistant (MDR) tumor phenotypes. Due to their extreme systemic toxicity and narrow therapeutic window, duocarmycins are generally unsuitable for use as standalone chemotherapeutic agents. Instead, they have gained significant prominence in modern oncology as cytotoxic payloads for antibody-drug conjugates (ADCs). In this format, the duocarmycin analog is linked to a monoclonal antibody that targets specific tumor-associated antigens, such as HER2 or CD70, allowing for targeted delivery and internalized release within cancer cells. This strategy leverages the drug's high potency while minimizing off-target damage to healthy tissues, as seen in clinical candidates like trastuzumab duocarmazine.

Other names

CC-1065 analogsDNA minor groove alkylating agentsCBI-type alkylatorsDuocarmycin ADuocarmycin SA

Duocarmycins bind to the minor groove of DNA with high sequence specificity and induce irreversible alkylation of the N3 position of adenine, leading to DNA strand breaks, inhibition of DNA synthesis, and subsequent apoptosis.